Rainer Henning
Consultant
Drug development in pharma and biotech
Axentis Pharma
Switzerland
Biography
Rainer Henning is a Consultant to Sirius Healthcare Partners. He has 30 years experience in all aspects of drug development in pharma and biotech settings from target and lead discovery to regulatory approval; he has also worked as a venture capitalist for several years. He has a deep network in the pharma, biotech and finance industry. He is currently CEO of Biomay, an Austrian immunotherapy company. His previous responsibilities include Deputy Head of Cardiovascular Research at Hoechst AG and Managing Director R&D for Nippon HMR (now part of Sanofi) and CEO of Fibrex Medical, Inc., a clinical stage biopharmaceutical company. His contributions were instrumental for the discovery and development of the Hoechst’s blockbuster ACE inhibitors ramipril and trandolapril. He has a Ph.D in chemistry from Justus-Liebig-University in Giessen, and did 2 years of post-doctoral work at Colorado State University.
Research Interest
pharma and biotech
